Results 221 to 230 of about 82,941 (302)

Glucose metabolic reprogramming: a novel strategy to enhance radiotherapy response to triple-negative breast cancer. [PDF]

Front Public Health
Gan L, Li Q, Yu B, Si J, Li Q, Chen W, Wang B.   +6 more
europepmc   +1 more source

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Evolution of ER-cut-off definition in clinical trials for triple negative breast cancer: trends and patterns over 15 years. [PDF]

Breast
Bonomi G, Napetti D, Griguolo G, Zanghì F, Girardi F, Lando S, Napolitano P, Landa G, La Commare M, Massa D, Guarneri V, Dieci MV.   +11 more
europepmc   +1 more source

Oxidative Stress and DNA Epigenetic Modifications in Cancer: Mechanisms and Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Reactive oxygen species (ROS) modulate DNA methyltransferases (DNMTs), ten‐eleven translocation family proteins (TETs) and their cofactors, reshaping 5‐methylcytosine (5mC)/5‐hydroxymethylcytosine (5hmC)/5‐formylcytosine (5fC) landscapes and gene expression in cancer cells. In turn, epigenetic control of antioxidant and metabolic pathways feeds back on
Xishan Yang, Qitai Chen, YuJie Yu, Yi Zang, Rujia Zheng, Zhe Zhang, Shuaijun Lu, Li Zhou   +7 more
wiley   +1 more source

Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies. [PDF]

Cancer Res
Ortega-Álvarez D, Tébar-García D, Casado-Peláez M, Olivares-Osuna D, Castillo-Agea E, Balibrea-Rull J, Barbella-Aponte RA, Pérez-Parra D, Musulén E, Guardia C, Vinuesa-Pitarch E, Sánchez-López ME, Postigo-Corrales F, Ballana E, Martínez-Cardús A, Margelí M, Esteller M, Fernández PL, Luengo-Gil G, Mereu E, Galán-Moya EM, Rodilla V.   +21 more
europepmc   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Chemotherapeutics as Immune Modulators for the Treatment of Triple-Negative Breast Cancer. [PDF]

Cancers (Basel)
Fines CB, Kelly S, McCarthy HO, Buckley NE.   +3 more
europepmc   +1 more source

Evaluation of Photophysical Properties and Biological Applications of Diarylmethanes

ChemistryOpen, Volume 15, Issue 6, June 2026.
The wide applications of diarylmethanes were investigated through various experimental and computational approaches. The solvent environment influences the electronic properties of diarylmethanes and hence their drug‐like properties. Interactions with PARP1 revealed stable binding supporting anticancer potential.
H. Ranjini Jenifer, Fateh V. Singh, M. M. Balamurali   +2 more
wiley   +1 more source